Ticker
ADIL

Price
0.40
Stock movement down
-0.02 (-5.09%)
Company name
Adial Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
10.71M
Ent værdi
7.29M
Pris/omsætning
-
Pris/bog
1.98
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-81.18%
3 års afkast
-38.32%
5 års afkast
-
10 års afkast
-
Senest opdateret: 2023-02-06

UDBYTTE

ADIL betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning-
Pris til egenkapital1.98
EV i forhold til salg-

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier26.85M
EPS (TTM)-0.61
FCF pr. aktie (TTM)-0.46

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsindkomst (TTM)-16.06M
Nettoindkomst (TTM)-15.70M
EPS (TTM)-0.61
EPS (1 år frem)-0.56

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenstmargin (TTM)-

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter5.75M
Nettotilgodehavender0.00
Omsætningsaktiver i alt6.77M
Goodwill248.97K
Immaterielle aktiver4.62K
Ejendomme, anlæg og udstyr0.00
Sum aktiver7.74M
Kreditor278.20K
Kortfristet/nuværende langsigtet gæld220.25K
Summen af kortfristede forpligtelser1.33M
Sum gæld2.33M
Aktionærernes egenkapital5.41M
Materielle nettoaktiver4.70M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-11.81M
Investeringsudgifter (TTM)0.00
Fri pengestrøm (TTM)-11.81M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-290.17%
Afkast af aktiver-202.74%
Afkast af investeret kapital-287.25%
Kontant afkast af investeret kapital-216.11%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning0.42
Daglig høj0.42
Daglig lav0.39
Daglig volumen111K
Højeste gennem alle tider8.33
1 års analytiker estimat8.50
Beta0.59
EPS (TTM)-0.61
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation1 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ADILS&P500
Nuværende prisfald fra top notering-95.21%-14.21%
Højeste prisfald-97.56%-56.47%
Højeste efterår dato12 Dec 20229 Mar 2009
Gennemsnitlig fald fra toppen-71.71%-11.49%
Gennemsnitlig tid til nyt højdepunkt104 days13 days
Maks. tid til nyt højdepunkt1023 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ADIL (Adial Pharmaceuticals Inc) company logo
Markedsværdi
10.71M
Markedsværdi kategori
Small-cap
Beskrivelse
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Personale
16
Investor relationer
-
SEC-indsendelser
Adm. direktør
William B. Stilley
Land
USA
By
Charlottesville
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley Po...
1. februar 2023
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisi...
1. december 2022
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to President...
14. november 2022
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enter...
19. oktober 2022
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of t...
26. september 2022
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 - Chronic Constrictive Injury Model (Rat) PNV-5030 - Chronic Constrictive Injury Model (Rat) CHARLOTTESVILLE, Va...
26. september 2022
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary Purnovate Inc achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory ...
6. september 2022
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 - DSS-induced Ulcerative Colitis Model (Mice) PNV-6005 - DSS-induced Ulcerative Colitis Mod...
6. september 2022
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisi...
1. september 2022
Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises are part of Zacks Screen of the Week article.
29. august 2022
Næste side